Rapid Screening of Novel Agents for Combination Therapy in Sarcomas

Table 1

Investigation, targeted agents used in study.

Agent	Mechanism of action	Source	Agreement
ABT-888	PARP inhibitor	AbbVie*	Single agent and with FDA approved
Dasatinib	Src, BCR-ABL inhibitor	BMS*	Single agent and with topoisomerase inhibitors or GX15-070
Etoposide	Topoisomerase II inhibitor	Commercial	FDA approved
GX15-070	BH3 mimetic	GeminX*	Single agent and with dasatinib or PXD101, and FDA approved
MK-2206	Akt inhibitor	Merck	Single agent and with dasatinib, MK-8669 or FDA approved
MK-8669	mTor inhibitor	Merck	Single agent and with dasatinib, MK-2206 or FDA approved
PXD101	HDAC inhibitor	CuraGen*	Single agent and with GX15-070
Saracatinib (AZD0530)	Src inhibitor	AstraZeneca*	Single agent and with saracatinib
Selumetinib; (AZD6244, ARRY-142886)	MEK-1/2 inhibitor	AstraZeneca*	Single agent and with saracatinib and FDA approved
Sorafenib	VEGF, RAF inhibitor	Commercial	FDA approved
Topotecan	Topoisomerase I inhibitor	Commercial	FDA approved
Triciribine	AKT inhibitor, nucleoside	Commercial	FDA approved
Vorinostat	HDAC inhibitor	Merck*	FDA approved

 *Obtained through CTEP N01-CM-62208.